ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SXTP / options
ONCO (30) GRI (34) EOCN (34) ERNA (33) ⌘ Pro Terminal β†’

60 Degrees Pharmaceuticals Inc. (SXTP) Options Positioning, Max Pain & Unusual Sweeps

$0.91 -3.65% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.90

60 Degrees Pharmaceuticals Inc. (SXTP) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $3.3M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SXTP Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.91 (-3.65% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SXTP ranks #523 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SXTP compare to ONCO and GRI in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, ONCO (Onconetix Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M) and GRI (GRI Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SXTP?
β–Ό

Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.90 (-0.85%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (38/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510038
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D+
Cash (6)Whales (6)SEC (11)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-8.8% Base Target
$9 Bull$1 Base$1 Bear
πŸ“¬ FREE SXTP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SXTP)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
πŸ” WHY SXTP SCORES 38/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime Γ— Technicals: 4% of 52W Range β€’ RSI-14 at 48.6 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
30
Grade E$0.90+2.2% Next Q
Q2 (-2Q)
33
Grade E$0.92-19.6% Next Q
Q3 (-1Q)
35
Grade E$0.74+23% Next Q
Current
38
Grade D-$0.91-7.8% Hist 90D Ξ±
Trajectory: E (30) β†’ D- (38)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SXTP Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SXTP currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($0.96) forces dealer call-delta covering toward $9.05.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SXTPβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSXTP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SXTP)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SXTP.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SXTP)

  • βœ“Walkthrough of SXTP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SXTP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.48%β–Ό DESCENDING CHANNEL
2026-11-03O $0.95H $0.95L $0.91C $0.91VOL 73.5K
RES: $1.58SUP: $0.55SMA50: $1.00SMA200: $1.76
$4.21$3.23$2.25$1.27$0.29RES $1.58SUP $0.55$0.912026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SXTP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SXTP Butterfly Map β†’ + Track SXTP β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +65.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SXTP today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SXTP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SXTP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SXTP)

Health Care Rank #523 of 1015 βš”οΈ ONCO vs SXTP Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SXTP vs. ONCO, GRI, EOCN, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, 60 Degrees Pharmaceuticals Inc. (SXTP) ranks #523 by composite RQD confidence (38/100, grade D-) and #970 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, SXTP leads on earnings valuation at N/A trailing P/E, while SXTP leads on capital efficiency and profitability with -35.0% ROIC and 22.3% gross margin. SXTP currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SXTP ACTIVE
60 Degrees Pharmaceuticals Inc.
D- 38/100 β€” 22.3% -35.0% -3.65% $3.3M Benchmark Subject
ONCO
Onconetix Inc.
E 30/100 β€” 77.6% -35.0% -3.24% $3.3M /onco-vs-sxtp β†’
GRI
GRI Bio Inc.
E 34/100 β€” β€” -35.0% -4.57% $3.3M /gri-vs-sxtp β†’
EOCN
Eocene Ltd.
E 34/100 β€” β€” -35.0% -7.54% $3.2M /eocn-vs-sxtp β†’
ERNA
Ernexa Therapeutics Inc.
E 33/100 β€” β€” -35.0% -1.01% $3.2M /erna-vs-sxtp β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001946563 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), 60 Degrees Pharmaceuticals Inc. (SXTP) reported GAAP revenue of $1.0M (+65.5% vs. FY2024 revenue of $607.6K , and +296.5% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$6.8M, and free cash flow of -$7.0M (-21.5% YoY). On the balance sheet, SXTP closed FY2025 with $5.4M in total assets against $144.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.0M -$7.4M -$6.8M -$7.0M $5.4M $144.0K
FY2024 (FY) 2024-12-31 $607.6K -$7.9M -$5.6M -$5.8M $5.8M $147.1K
FY2023 (FY) 2023-12-31 $253.6K -$3.8M -$4.5M -$4.5M β€” β€”

3. SXTP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.91 (-3.65% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SXTP ranks #523 in composite RQD confidence.

How does SXTP compare to ONCO and GRI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, ONCO (Onconetix Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M) and GRI (GRI Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SXTP?

Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SXTP trading relative to its 50-day, 200-day, and 52-week technical levels?

SXTP last traded at $0.91 (-3.65% on volume of 46,825 shares), positioning the stock -9.00% below its 50-day simple moving average ($1.00) and -48.30% below its 200-day simple moving average ($1.76). Across its 52-week range of $0.59 to $8.62, SXTP sits at the 4.0% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $1.02).

Direct Sub-Reports: SXTP RQD Cockpit SXTP 12M Forecast SXTP Earnings & Move SXTP Dividends & DRIP SXTP Insiders & 13F SXTP Whale Options SXTP Profit Sankey SXTP News & Why
ROARABLE RATING BRIEF β€’ RQD 38/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

SXTP β€” 60 Degrees Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

60 Degrees Pharmaceuticals Inc. (SXTP) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.91 (-3.65% 1D, market capitalization $3.3M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 22.3%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of 0.04x.

2. Business Model, Unit Margins & SEC Financial Trajectory

60 Degrees Pharmaceuticals Inc. (SXTP) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue was $1.0M for FY 2025, . β€” for further detail on how the company earns revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), 60 Degrees Pharmaceuticals Inc. (SXTP) reported $1.0M in annual revenue (up from $607.6K in FY2024, +65.5% YoY) and -$7.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($253.6K revenue, -$3.8M net income) through FY2025, SXTP scaled operating cash flow to -$6.8M and free cash flow to -$7.0M, backed by $5.4M in total assets against $144.0K in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 6/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.59 – $8.62 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded.

  • Key Question #1: Can SXTP sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.0M and free cash flow of -$7.0M, how will capital allocation balance growth reinvestment against $144.0K in total debt?
  • Key Question #3: How sensitive is SXTP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SXTP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for 60 Degrees Pharmaceuticals Inc. (SXTP) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SXTP Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SXTP Bull vs. Bear Conversation Board β€” What's Your Call at $0.91?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SXTP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SXTP:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $1.22 (+29.8%)
πŸ“Œ Pinned Debate

Reported debt is small at $0.1M against $1.5M in cash, giving the balance sheet a low leverage profile (Debt/Equity 0.04).

Here is why I am bullish on SXTP here at $0.94: Reported debt is small at $0.1M against $1.5M in cash, giving the balance sheet a low leverage profile (Debt/Equity 0.04).. Compare SXTP's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.89 are getting bought.

VolSurface_Trader πŸ‚ BULL

@ShortSeller_Dan Shorting a 6/20 institutional whale-flow stock at $0.94 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER β€’ Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.75 (-20.2%)
Spot @ $0.94

Free cash flow was -$7.0M in FY 2025 against $1.5M in cash, with ROIC at -35% and no reported analyst coverage.

Free cash flow was -$7.0M in FY 2025 against $1.5M in cash, with ROIC at -35% and no reported analyst coverage.. Look at the math on SXTP: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.83 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%